ArticleBMC infectious diseases2025
Development of a machine learning model for early pulmonary tuberculosis diagnosis using blood test biomarkers.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) is a major global health threat, causing 10.6 million new cases and 1.3 million deaths in 2022. Early diagnosis is crucial, but current methods are often costly and slow for resource-limited settings. This study aimed to develop a rapid, low-cost diagnostic tool using routine blood indicators.
methodsWe retrospectively analyzed data from 728 TB patients and 2,718 healthy controls. The training set was balanced using the ROSE technique. We trained seven machine learning models, using LASSO regression and forward selection to identify optimal features. The final model was interpreted with SHAP and deployed as an interactive Shiny application.
resultsThe Gradient Boosting Machine (GBM) model performed optimally on the test set (AUC = 0.831, specificity = 0.855, sensitivity = 0.644). SHAP analysis identified platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and platelet distribution width (PDW) as key predictors. Lowering the classification threshold to 0.24 increased sensitivity to 83.6% (specificity 59.9%), demonstrating its screening potential. An interactive web application was developed to enhance clinical utility.
conclusionThis study delivers a validated GBM model using routine blood tests as a cost-effective TB screening tool. Its high specificity can reduce unnecessary follow-up tests. The model’s core predictors are interpretable and provide biological insights into the inflammatory response in TB. The accompanying Shiny app increases accessibility, making it a promising tool for resource-limited settings. RECOMMENDATIONS: We propose a phased diagnostic strategy: use this model with a low threshold (0.24) for high-sensitivity initial screening, followed by confirmatory molecular testing for positive cases. This approach balances high detection rates with resource optimization. Future work should include prospective validation with cohorts including other respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.